ArticleFrontiers in medicine2026
Omalizumab treatment for chronic spontaneous urticaria coinciding with marked improvement of vitiligo: a case report.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report the case of a 49-year-old female patient with a history of hyperthyroidism and long-standing vitiligo for over two decades, who presented with a 6-year history of chronic spontaneous urticaria (CSU) refractory to conventional antihistamine therapy. She was subsequently initiated on subcutaneous omalizumab. This treatment not only led to significant control of her urticaria but also resulted in the unexpected observation of repigmentation of vitiligo lesions on the face and neck. As of the last follow-up in July 2025, the patient remained on omalizumab therapy with sustained improvement in both conditions. This case highlights a potential novel therapeutic effect of omalizumab on vitiligo, warranting further clinical and mechanistic investigation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.